Stock Analiz

GENELUX Corp GNLX

Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026

$1.86Market cap $84M
Open the interactive analysis →

GENELUX Corp (GNLX) is a healthcare company listed in the US with a market value of about $84M. In fiscal year 2025 it had revenue of $8000 and net income of -$32M, a net margin of -401812.5%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -124%.

About GENELUX

GENELUX is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. Revenue went from $11M in 2022 to $8000 in 2025, a decline of about 91.0% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 308% over three years (dilution for shareholders). It spends 248138% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S10,548.0
P/B5.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-34.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)0.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-198000.0%
ROIC (5-yr avg.)-123.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue$8000$8000$170000$11M
Net income-$32M-$30M-$28M-$5M
Free cash flow-$26M-$22M-$21M-$4M
EPS (diluted)$-0.86$-0.95$-1.16$-0.57
Net margin-401800.0%-373400.0%-16645.3%-47.0%
ROIC-198.3%-89.0%-83.4%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does GENELUX pay a dividend?

Not currently.

Is GENELUX a good stock to buy?

We do not give buy or sell advice. GENELUX scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.